Q1 EPS Forecast for Astria Therapeutics Decreased by Analyst
Astria Therapeutics, Inc. (NASDAQ:ATXS – Free Report) – Equities research analysts at Wedbush cut their Q1 2025 earnings estimates for Astria Therapeutics in a note issued to investors on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings of ($0.46) per share for the quarter, down from their […]
